NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.

被引：0
|
作者：
Tanizaki, Junko
Yonemori, Kan
Akiyoshi, Kohei
Minami, Hironobu
Ueda, Hiroki
Takiguchi, Yuichi
Kondoh, Chihiro Nakayama
Segawa, Yoshihiko
Takahashi, Shin
Iwamoto, Yasuo
Kidera, Yasuhiro
Fukuoka, Kazuya
Nakamura, Yasushi
Chiba, Yasutaka
Nishio, Kazuto
Nakagawa, Kazuhiko
Hayashi, Hidetoshi
机构：
[1] Kishiwada City Hosp, Kishiwada, Japan
[2] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan
[3] Osaka City Gen Hosp, Osaka, Japan
[4] Kobe Univ, Grad Sch Med, Dept Med Oncol Hematol, Kobe, Hyogo, Japan
[5] Wakayama Med Univ, Pulm Med & Oncol, Wakayama, Japan
[6] Chiba Univ, Grad Sch Med, Dept Med Oncol, Chiba, Japan
[7] Toranomon Gen Hosp, Dept Med Oncol, Tokyo, Japan
[8] Saitama Med Univ, Int Med Ctr, Hidaka, Japan
[9] Tohoku Univ Hosp, Dept Med Oncol, Sendai, Miyagi, Japan
[10] Hiroshima CIty HIroshima Citizens Hosp, Hiroshima City Hosp Org, Dept Med Oncol, Hiroshima, Japan
[11] Kindai Univ Hosp, Osaka, Japan
[12] Kindai Univ, Fac Med, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
106
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
    Tanizaki, J.
    Yonemori, K.
    Akiyoshi, K.
    Minami, H.
    Ueda, H.
    Takiguchi, Y.
    Miura, Y.
    Segawa, Y.
    Takahashi, S.
    Iwamoto, Y.
    Kidera, Y.
    Fukuoka, K.
    Ito, A.
    Chiba, Y.
    Sakai, K.
    Nishio, K.
    Nakagawa, K.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 216 - 226
  • [2] A phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (CUP) (NivoCUP)
    Noguchi, Emi
    Tanizaki, Junko
    Akiyoshi, Kohei
    Toyoda, Masanori
    Ueda, Hiroki
    Takiguchi, Yuichi
    Ozaki, Yukinori
    Segawa, Yoshihiko
    Takahashi, Shin
    Okikawa, Yoshiko
    Kidera, Yasuhiro
    Fukuoka, Kazuya
    Nakamura, Yasushi
    Chiba, Yasutaka
    Sakai, Kazuko
    Yonemori, Kan
    Minami, Hironobu
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    ANNALS OF ONCOLOGY, 2021, 32 : S286 - S286
  • [3] A phase II study on the efficacy of Nivolumab in Japanese patients with cancer of unknown primary (CUP) (NivoCUP)
    Tanizaki, Junko
    Hayashi, Hidetoshi
    Minami, Hironobu
    Arai, Makoto
    Takahashi, Shin
    Segawa, Yoshihiko
    Ozaki, Yukinori
    Ueda, Hiroki
    Akiyoshi, Kohei
    Iwamoto, Yasuo
    Yonemori, Kan
    Kidera, Yasuhiro
    Fukuoka, Kazuya
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Updated analysis from a phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (NivoCUP)
    Funakoshi, Yohei
    Tanizaki, Junko
    Yonemori, Kan
    Akiyoshi, Kohei
    Ueda, Hiroki
    Takiguchi, Yuichi
    Miura, Yuji
    Segawa, Yoshihiko
    Komine, Keigo
    Okikawa, Yoshiko
    Kidera, Yasuhiro
    Fukuoka, Kazuya
    Ito, Akihiko
    Chiba, Yasutaka
    Sakai, Kazuko
    Minami, Hironobu
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    ANNALS OF ONCOLOGY, 2023, 34 : S1419 - S1419
  • [5] Phase II trial of sintilimab in cancer of unknown primary.
    Huey, Ryan W.
    Raghav, Kanwal Pratap Singh
    Estrella, Jeannelyn
    Higbie, Victoria
    Le, Phat
    Bent, Alisha Heather
    Matamoros, Aurelio
    Lano, Elizabeth A.
    Willett, Anneleis
    Nguyen, Vincent
    Escano, Michelle
    Wilson, Kaye F.
    Lin, Heather Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 825 - 825
  • [6] Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary.
    Varadhachary, Gauri R.
    Raghav, Kanwal Pratap Singh
    Pant, Shubham
    Janku, Filip
    Fu, Siqing
    Hong, David S.
    Piha-Paul, Sarina Anne
    Colen, Rivka R.
    Subbiah, Vivek
    Painter, Jeane
    Tsimberidou, Apostolia Maria
    Stephen, Bettzy
    Karp, Daniel D.
    McQuinn, Lacey
    Mendoza, Tito R.
    Hess, Kenneth R.
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study
    Mariette, Xavier
    Seror, Raphaele
    Quartuccio, Luca
    Baron, Gabriel
    Salvin, Sara
    Fabris, Martina
    Desmoulins, Frederic
    Nocturne, Gaetane
    Ravaud, Philippe
    De Vita, Salvatore
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (03) : 526 - 531
  • [8] A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
    Goto, Y.
    Okada, M.
    Kijima, T.
    Aoe, K.
    Kato, T.
    Fujimoto, N.
    Nakagawa, K.
    Takeda, Y.
    Hida, T.
    Kanai, K.
    Imamura, F.
    Oizumi, S.
    Takahashi, T.
    Takenoyama, M.
    Tanaka, H.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1883 - S1883
  • [9] A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT)
    Aoe, Keisuke
    Okada, Morihito
    Kijima, Takashi
    Kato, Terufumi
    Fujimoto, Nobukazu
    Nakagawa, Kazuhiko
    Takeda, Yuichiro
    Hida, Toyoaki
    Kanai, Kuninobu
    Imamura, Fumio
    Oizumi, Satoshi
    Takahashi, Toshiaki
    Takenoyama, Mitsuhiro
    Tanaka, Hiroshi
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
    Daver, Naval
    Garcia-Manero, Guillermo
    Basu, Sreyashi
    Boddu, Prajwal C.
    Alfayez, Mansour
    Cortes, Jorge E.
    Konopleva, Marina
    Ravandi-Kashani, Farhad
    Jabbour, Elias
    Kadia, Tapan
    Nogueras-Gonzalez, Graciela M.
    Ning, Jing
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Andreeff, Michael
    Pierce, Sherry A.
    Gordon, Tauna
    Kornblau, Steven M.
    Flores, Wilmer
    Alhamal, Zainab
    Bueso-Ramos, Carlos
    Jorgensen, Jeffrey L.
    Patel, Keyur P.
    Blando, Jorge
    Allison, James P.
    Sharma, Padmanee
    Kantarjian, Hagop
    CANCER DISCOVERY, 2019, 9 (03) : 370 - 383
12345